Phase II Clinical Trial of Etanercept Plus Extracorporeal Photopheresis GVHD Prophylaxis Following Unrelated Donor Reduced Intensity Transplant

被引：0
|
作者：
Kitko, Carrie L. [1 ]
Braun, Thomas [2 ]
Schuler, Charles [3 ]
Choi, Sung Won [1 ]
Yanik, Gregory [1 ]
Pawarode, Attaphol [4 ]
Magenau, John [4 ]
Taylor, Austin [5 ]
Ferrara, James L. M. [5 ]
Couriel, Daniel R. [4 ]
Levine, John [1 ]
机构：
[1] Univ Michigan, Pediat Blood & Marrow Transplant Program, Ann Arbor, MI 48109 USA
[2] Univ Michigan, Ann Arbor, MI 48109 USA
[3] Univ Michigan, Dept Internal Med, Ann Arbor, MI 48109 USA
[4] Univ Michigan, Adult Blood & Marrow Transplant Program, Ann Arbor, MI 48109 USA
[5] Icahn Sch Med Mt Sinai, New York, NY 10029 USA
来源：
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION | 2015年 / 21卷 / 02期
关键词：
D O I：
10.1016/j.bbmt.2014.11.537
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
490
引用
收藏
页码：S337 / S337
页数：1
相关论文
共 50 条
  • [41] Prophylaxis of graft-versus-host disease (GVHD) with pentostatin, tacrolimus, and "Mini" - Methotrexate (MTX): A phase I/II controlled, randomized study in unrelated donor (UD) transplatation
    de Lima, Marcos
    Andersson, B.
    Fernandez-Vina, M.
    Giralt, S.
    Couriel, D.
    Shpall, V.
    Popat, U.
    Qazilbash, M.
    Alousi, A.
    Cano, P.
    Bosque, D.
    Hosing, C.
    Qureshi, S.
    de Padua, L.
    Munsell, M.
    Anderlini, P.
    Jones, R.
    Westmoreland, M.
    Gulbis, A.
    Champlin, R.
    BLOOD, 2007, 110 (11) : 20A - 20A
  • [42] A phase II study of post-transplant cyclophosphamide combined with tacrolimus for GVHD prophylaxis after HLA-matched related/unrelated allogeneic hematopoietic stem cell transplantation
    Nakamae, Hirohisa
    Nakane, Takahiko
    Okamura, Hiroshi
    Koh, Hideo
    Nakashima, Yasuhiro
    Hirose, Asao
    Nakamae, Mika
    Nishimoto, Mitsutaka
    Kuno, Masatomo
    Makuuchi, Yosuke
    Harada, Naonori
    Takakuwa, Teruhito
    Hino, Masayuki
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2022, 115 (01) : 77 - 86
  • [43] A phase II study of post-transplant cyclophosphamide combined with tacrolimus for GVHD prophylaxis after HLA-matched related/unrelated allogeneic hematopoietic stem cell transplantation
    Hirohisa Nakamae
    Takahiko Nakane
    Hiroshi Okamura
    Hideo Koh
    Yasuhiro Nakashima
    Asao Hirose
    Mika Nakamae
    Mitsutaka Nishimoto
    Masatomo Kuno
    Yosuke Makuuchi
    Naonori Harada
    Teruhito Takakuwa
    Masayuki Hino
    International Journal of Hematology, 2022, 115 : 77 - 86
  • [44] Multicentre adaptive randomised trial of GvHD prophylaxis following unrelated donor stem cell transplantation comparing Thymoglobulin versus calcineurin inhibitor-based or sirolimus-based post-transplant cyclophosphamide (Methods of T cell Depletion, MoTD trial)
    Chakraverty, Ronjon
    Kempshall, Emma
    Dignan, Fiona
    Bloor, Adrian
    Collin, Matthew
    Raj, Kavita
    Davies, Jeff
    Potter, Victoria
    Malladi, Ram
    Smith, Siobhan
    Gates, Simon
    Gaskell, Charlotte
    Bishop, Rebecca
    Hodgkinson, Andrea
    Smith, Gabrielle
    BMJ OPEN, 2025, 15 (01):
  • [45] Phase II Trial of Reduced-Intensity Fludarabine, Melphalan, and Total Body Irradiation Conditioning Results in Favorable Outcomes with Haploidentical Donor Peripheral Blood Stem Cell Transplant
    Elmariah, Hany
    Kim, Jongphil
    Mishra, Asmita
    Faramand, Rawan
    Perez, Lia
    Lazaryan, Aleksandr
    Khimani, Farhad
    Liu, Hien
    Ochoa-Bayona, Jose L.
    Nieder, Michael
    Figura, Nicholas
    Robinson, Timothy J.
    Nishihori, Taiga
    Anasetti, Claudio
    Pidala, Joseph A.
    Bejanyan, Nelli
    BLOOD, 2023, 142
  • [46] A PROSPECTIVE PHASE I/II TRIAL OF BORTEZOMIB-BASED GRAFT-VERSUS-HOST-DISEASE PROPHYLAXIS IN HLA-MISMATCHED UNRELATED DONOR REDUCED-INTENSITY CONDITIONING HEMATOPOIETIC STEM CELL TRANSPLANTATION: ENCOURAGING SAFETY, EFFICACY, AND SURVIVAL
    Koreth, J.
    Stevenson, K. E.
    Kim, H. T.
    Bindra, B.
    McDonough, S.
    Ho, V. T.
    Cutler, C. S.
    Armand, P.
    Soiffer, R. J.
    Antin, J. H.
    Ritz, J.
    Alyea, E. P.
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2011, 17 (02) : S165 - S166
  • [47] Preemptive DLI without withdrawal of immunosuppression to promote complete donor T-cell chimerism results in favorable outcomes for high-risk older recipients of alemtuzumab-containing reduced-intensity unrelated donor allogeneic transplant: a prospective phase II trial
    S R Solomon
    C A Sizemore
    X Zhang
    S Brown
    H K Holland
    L E Morris
    A Bashey
    Bone Marrow Transplantation, 2014, 49 : 616 - 621
  • [48] Preemptive DLI without withdrawal of immunosuppression to promote complete donor T-cell chimerism results in favorable outcomes for high-risk older recipients of alemtuzumab-containing reduced-intensity unrelated donor allogeneic transplant: a prospective phase II trial
    Solomon, S. R.
    Sizemore, C. A.
    Zhang, X.
    Brown, S.
    Holland, H. K.
    Morris, L. E.
    Bashey, A.
    BONE MARROW TRANSPLANTATION, 2014, 49 (05) : 616 - 621
  • [49] Fatal donor-derived Epstein–Barr virus-associated post-transplant lymphoproliferative disorder following reduced intensity volunteer-unrelated bone marrow transplant for myelodysplastic syndrome
    AYL Ho
    S Adams
    H Shaikh
    A Pagliuca
    S Devereux
    GJ Mufti
    Bone Marrow Transplantation, 2002, 29 : 867 - 869
  • [50] National Marrow Donor Program-Sponsored Multicenter, Phase II Trial of HLA-Mismatched Unrelated Donor Bone Marrow Transplantation Using Post-Transplant Cyclophosphamide
    Shaw, Bronwen E.
    Jimenez-Jimenez, Antonio Martin
    Burns, Linda J.
    Logan, Brent R.
    Khimani, Farhad
    Shaffer, Brian C.
    Shah, Nirav N.
    Mussetter, Alisha
    Tang, Xiao-Ying
    McCarty, John M.
    Alavi, Asif
    Farhadfar, Nosha
    Jamieson, Katarzyna
    Hardy, Nancy M.
    Choe, Hannah
    Ambinder, Richard F.
    Anasetti, Claudio
    Perales, Miguel-Angel
    Spellman, Stephen R.
    Howard, Alan
    Komanduri, Krishna, V
    Luznik, Leo
    Norkin, Maxim
    Pidala, Joseph A.
    Ratanatharathorn, Voravit
    Confer, Dennis L.
    Devine, Steven M.
    Horowitz, Mary M.
    Bolanos-Meade, Javier
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (18) : 1971 - +
12345